In the MedTech world, few processes are as universally dreaded as regulatory submissions. Despite advancements across R&D and commercialization, the path to regulatory approval remains bogged down by manual workflows, disconnected systems, and ever-changing global requirements.
In 2026, that complexity has intensified significantly. AI and machine learning tools have been widely adopted to streamline regulatory processes, with FDA reporting over 500 drug submissions with AI components reviewed between 2016–2023 and that number continuing to grow rapidly. Simultaneously, EUDAMED’s mandatory rollout has added new data submission obligations for every manufacturer selling into the EU, and eCTD v4.0 is reshaping how electronic dossiers are structured and validated. For regulatory teams already stretched thin, the stakes of submission inefficiency have never been higher or the opportunity for automation never greater.
RegDesk is leading the charge, helping MedTech innovators bring products to market faster with purpose-built submission automation.
The Traditional Submission Process: Why It’s Slowing You Down
The fragmentation problem has grown more acute as submission format requirements have evolved. The FDA updated eCTD validation criteria and file format specifications multiple times in 2025 alone; each change requiring teams to verify their existing templates and dossier components remain compliant. For manufacturers submitting to multiple markets simultaneously, managing these format differences manually is a compounding drain on resources.
Add to this the EUDAMED data obligations now in effect from May 2026, which require structured device data across 120+ fields per entry to be validated and submitted before any new device can be placed on the EU market. Manual processes simply cannot keep pace with this level of structured data management at scale.
All of this adds up to long hours, regulatory burnout, and misalignment across cross-functional teams who are rarely working from a single source of truth.
The Impact: Faster, Smarter, Scalable Submissions
The difference automation makes is not theoretical, it is measurable. In 2025, the median time from submission to FDA 510(k) clearance for AI/ML medical devices was 142 days, with an average of 150 days, yet a quarter of all devices were cleared in under 90 days, demonstrating the potential for a rapid path to market when submissions are well-prepared. The gap between a well-prepared and a poorly prepared submission is not minor; it can mean months of delay, multiple rounds of deficiency responses, and significant opportunity cost.
Automation closes that gap. Submissions that once took six months to prepare can now be completed in days. Teams that previously managed only a few markets at a time can now coordinate global launches in parallel with documentation that is validated against current regional requirements before it ever reaches a reviewer’s desk.
In a landmark development, the FDA launched its own agency-wide generative AI tool, “Elsa”, in June 2025, signaling the agency’s embrace of AI for scientific review. For manufacturers, this means submissions reviewed by AI-assisted processes must be structured, complete, and consistent; raising the bar for submission quality and making internal automation not just a competitive advantage but a practical necessity.
Key Capabilities to Look For in a Submission Automation Platform
The capability requirements for a submission automation platform have expanded meaningfully in 2026. Beyond pre-configured country-specific templates and intelligent document reuse, look for:
AI governance support: For EU markets, AI-powered medical devices must now comply with both MDR/IVDR and the EU AI Act, as confirmed by joint MDCG and AI Board FAQs in 2025. Platforms should support the documentation requirements for AI-enabled devices, including Predetermined Change Control Plans (PCCPs), lifecycle management records, and bias analysis documentation; increasingly required components of modern submissions.
EUDAMED data integration: With EUDAMED mandatory from May 28, 2026, a submission platform that cannot support structured UDI and device data submission is missing a foundational capability. Look for platforms that connect regulatory documentation with EUDAMED data fields to eliminate dual data entry and reduce inconsistency risk.
eCTD v4.0 readiness: FDA has been accepting eCTD v4.0 submissions since September 2024 and continues updating validation criteria; platforms should support both v3.2.2 and v4.0 to future-proof your submission infrastructure.
Collaboration tools with audit trails, real-time validation against regional formats, and integration with regulatory intelligence systems remain essential and the right solution should scale as your portfolio and global footprint grow.
How RegDesk Is Redefining Submission Management
RegDesk’s Submission Builder was designed specifically for the complexity and speed required in today’s MedTech environment. In 2026, that environment includes mandatory EUDAMED data obligations, eCTD v4.0 format requirements, AI Act documentation layers, and an FDA increasingly using AI tools in its own review process.
With a centralized platform that enables real-time collaboration, reusable dossier components, and built-in regulatory intelligence across 120+ markets, RegDesk empowers teams to create market-ready submissions with unprecedented efficiency. Submission Builder supports both global standardization and local customization so you can build a compliant core dossier and automatically adapt it to meet country-specific requirements, whether that’s an FDA 510(k), an EU MDR technical file, a Health Canada Class III application, or a TGA ARTG submission.
The platform validates content against regional formats before submission, helping teams avoid common mistakes and last-minute surprises: the kind that result in deficiency letters, timeline delays, and missed market windows.
Real-World Value: Customer Results or Testimonials
The business impact of submission automation is direct and measurable. One mid-sized device manufacturer using the RegDesk platform reported cutting submission preparation time by more than 70%, freeing their RA team to pursue new market opportunities instead of chasing document updates. Another noted how RegDesk eliminated version control issues entirely, streamlining collaboration across geographies and time zones.
These results reflect a broader industry shift. In 2025, 295 AI/ML medical devices received FDA clearance: a record year demonstrating that manufacturers with strong submission infrastructure can move from development to cleared product faster than ever. The companies best positioned to capture those approvals are the ones whose regulatory operations can match the pace of their innovation.
Conclusion
In 2026’s regulatory environment, speed and accuracy are not optional, they are the price of market access. EUDAMED is mandatory. eCTD is evolving. The EU AI Act is adding new documentation layers. The FDA is using AI in its own review process. Manual submission processes built for a simpler era cannot keep pace.
Automation offers a smarter, faster way to manage this complexity: reducing risk, eliminating rework, and freeing regulatory teams to focus on the strategic decisions that drive business growth. Whether you are preparing your first 510(k), expanding into the EU market, or managing a global portfolio across dozens of markets simultaneously, the time to modernize your submission process is now.
With RegDesk’s Submission Builder, regulatory affairs becomes a true driver of competitive advantage, not an obstacle that holds your product back.
Q&A:
- Why is regulatory submission automation more important in 2026 than ever before? The regulatory environment in 2026 is more complex, faster-moving, and more data-intensive than at any point in recent history. EUDAMED’s mandatory rollout adds structured device data obligations for EU market access. The FDA launched its own AI review tool in 2025, raising expectations for submission completeness and structure. The EU AI Act begins applying high-risk AI obligations to medical devices from August 2026, adding new documentation layers. Manual workflows simply cannot keep pace with this level of concurrent, evolving requirement.
- How much time can submission automation actually save? Results vary by company size and portfolio complexity, but the gains are significant. RegDesk customers have reported cutting submission preparation time by more than 70%. At the industry level, well-prepared 510(k) submissions in 2025 achieved FDA clearance in under 90 days — a quarter of all AI/ML devices cleared in that timeframe; demonstrating that preparation quality directly drives timeline outcomes.
- What formats does a modern submission automation platform need to support in 2026? At minimum: FDA 510(k) and De Novo formats, eCTD v3.2.2 and v4.0 (both currently supported by FDA), EU MDR and IVDR technical file structures, EUDAMED UDI/Device data formats, Health Canada Class II–IV submission formats, and TGA Essential Principles documentation. Platforms that support multi-market parallel submissions with a shared core dossier and local adaptations provide the greatest efficiency advantage.
- What is eCTD v4.0 and does my submission platform need to support it? eCTD v4.0 has been accepted by the FDA for new applications since September 2024, with FDA continuing to update validation criteria through 2025. Both v3.2.2 and v4.0 are currently supported, but FDA will eventually transition to v4.0 only. Platforms that support both versions now protect manufacturers from having to rebuild submission infrastructure when that transition occurs.
- How does the EU AI Act affect medical device regulatory submissions? AI-enabled medical devices that are classified as high-risk under the EU AI Act must comply with both MDR/IVDR and AI Act requirements: a dual compliance obligation confirmed by joint MDCG and AI Board FAQs in 2025. High-risk AI obligations begin applying from August 2026. For submission teams, this means technical files for AI-enabled devices now need to include AI-specific documentation: model descriptions, data lineage, bias analyses, human oversight mechanisms, and, where applicable, Predetermined Change Control Plans (PCCPs).
- What does EUDAMED mean for my submission workflow? EUDAMED is no longer a separate database project, it is now a mandatory submission channel for device registration in the EU from May 28, 2026. For submission teams, this means that EUDAMED data entry (Actor registration, UDI/Device registration with 120+ data fields per entry) is now part of the pre-market process, not a separate administrative task. Platforms that integrate EUDAMED data management with technical file preparation eliminate dual data entry and reduce the risk of inconsistencies between what is submitted in EUDAMED and what is documented in the technical file.
- Can automation help with multi-market global submissions? Yes, and this is where the ROI is most dramatic. Manual multi-market submissions require teams to rebuild much of the same content from scratch for each market, with only minor variations. Automation platforms with intelligent document reuse and market-specific template libraries allow teams to build a compliant core dossier once and adapt it automatically for each target market, turning what was a sequential, months-long process into a parallel, days-long one.
- What should I look for when evaluating a submission automation platform? Look for: pre-configured, regularly updated country-specific templates; intelligent document reuse and version control; built-in regulatory intelligence aligned with current market requirements; EUDAMED data integration; eCTD v4.0 support; AI-enabled device documentation support (PCCP, lifecycle records); multi-market parallel submission capabilities; real-time collaboration with full audit trails; and the ability to scale as your portfolio grows. The right platform should reduce manual work, increase control, and grow with your regulatory strategy.
